Three innovative studies at AACR IO 2026 presented new ways for CAR T cells and antibody-lectin chimeras to tackle...
Although not common, a cancer diagnosis during pregnancy or the onset of a pregnancy while a woman is receiving...
Earlier this month, over 21,000 researchers, clinicians, patients, and other stakeholders gathered at the AACR Annual Meeting 2023 to...
Historically, most cancer drugs have been tested separately in adults and children. For the approval of new drugs for...
“Are you ready to have a great meeting?” Robert Vonderheide, MD, DPhil, asked the nearly 11,000 attendees gathered in...
When Monica Bertagnolli, MD, was appointed director of the National Cancer Institute in 2022, she became the first woman...
The 2015 approval of an immune checkpoint inhibitor for renal cell carcinoma (RCC) provided a much-needed new treatment option...
The plenary program of the AACR Annual Meeting 2023 kicked off Saturday, April 15, with a session titled “Beating...
As 21,000 cancer researchers, clinicians, policymakers, and patient advocates thronged the Orange County Convention Center, Margaret Foti, PhD, MD...
The American Association for Cancer Research (AACR) is proud to offer Global Scholar-in-Training Awards (GSITA) to support the career...
With the approval of new anticancer therapeutics, more treatment options become available for patients. Some therapies are new to...